Cibc World Markets Corp Has $5.50 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Cibc World Markets Corp grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,763 shares of the medical device company's stock after buying an additional 7,786 shares during the quarter. Cibc World Markets Corp's holdings in DexCom were worth $5,503,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter worth about $25,000. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of DexCom in the 4th quarter worth approximately $49,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 1.7 %

Shares of DXCM stock traded down $1.31 during trading on Friday, hitting $73.80. 5,560,851 shares of the company were exchanged, compared to its average volume of 3,922,409. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a P/E/G ratio of 2.30 and a beta of 1.28. The business's 50-day simple moving average is $83.33 and its 200 day simple moving average is $76.98. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Canaccord Genuity Group lifted their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Finally, Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.